Viatris (VTRS)
Health Care · generic and specialty pharmaceuticals · NASDAQ
Viatris is a global healthcare company providing a broad range of high-quality, affordable medicines across both developed and emerging markets.
What Viatris does
Viatris is a global pharmaceutical company focused on providing access to medicine through a diverse portfolio of branded, generic, and complex pharmaceutical products. The company operates globally across segments including Developed Markets, Emerging Markets, Greater China, and JANZ, and has recently invested in clinical development programs like selatogrel and cenerimod. Viatris was formed through the combination of Mylan and Pfizer's Upjohn Business.
Themes: generic pharmaceuticals, branded medicine access, global pharmaceutical supply chain, drug development pipeline, antiretrovirals, complex generics
Fundamentals
- Price$16.32 as of 2026-08-21 close
- Market cap$18.7B as of 2026-08-21
- 1-year return+52.7% 2025-08-21 close $10.69 → 2026-08-21 close $16.32
- P/En/a negative earnings
- Net margin-2.8% as of 2026-08-24
- Gross margin+40.3% as of 2026-08-24
- ROE-2.8% as of 2026-08-24
- Debt / equity0.94 as of 2026-08-24
- Revenue growth (YoY)+4.4% as of 2026-08-24
- Revenue CAGR (3y)-4.2% SEC XBRL
- Beta0.88 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +2.7%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How VTRS compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- indicated dividend yieldmiddle range 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
VTRS is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no valuation data.
Short-term score
36.1 #1529 of 1,704 scored · #221 of 240 in Health Care
Trend 46th: a "golden cross" — its 50-day average is above its 200-day; catalysts 41st: the analyst consensus rating is unchanged since the prior reading; weakest is volume and participation 20th: trading volume is about normal versus its 30-day average.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Viatris looks technically
Viatris (VTRS) is trading 14.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 224 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 7 trading days ago.
Trend
7
| Distance from the 200-day | it is trading 14.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +14.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $16.60 | $16.60 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $14.30 | $14.30 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 224 trading days ago — a "golden cross", a bullish long-term signal | 224 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend) | 20.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30) | 44.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($15.88 to $18.39) — its "stochastic" reading is 18 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 17.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $18.39 | $18.39 |
|---|---|---|
| From the 52-week high | it is 11.3% below its 52-week high (its highest price of the past year) | -11.3% |
| Above the 52-week low | it is 73.1% above its 52-week low (its lowest price of the past year) | +73.1% |
| Below the 52-week high | it is 11.3% below its highest point of the past year | 11.3% |
| Since a 20-day breakout | it made a new 20-day low about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day high about 19 trading days ago | 19 sessions |
| All-time high | its highest closing price on record is $76.69 (set on 2015-04-24) | $76.69 |
| Given back of the 52-week move | over the past year its closes ranged ($9.49 to $17.86), and it has given back roughly a quarter of its rise from last year’s low — 18% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $12.42 to $12.69. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 18.4% |
| From the all-time high | it is 78.7% below its all-time high | -78.7% |
| Nearest price level | it is trading 2.3% above a support level at $15.95 — a price it turned at three times since 2026-05-19, most recently on 2026-08-14. Since 2024-08-21 it has 14 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.3% |
| All-time low | its lowest closing price on record is $1.00 (set on 1980-10-28) | $1.00 |
| Above the all-time low | it is 1532.0% above its all-time low | +1,532% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 64th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4628 between its high and its low — about 2.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4628 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $15.36 and $18.28 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $15.36 – $16.82 – $18.28 |
| Typical daily range (% of price) | its price moves about 2.8% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.8% |
| Stretch from the 200-day average | it is trading 4.4 daily ranges above its 200-day average price (14.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.64× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.7% |
|---|---|---|
| Gap filled | a 2.8% gap up opened on 2026-08-06 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 11 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.6 percentage points (the stock lost 7.2% while the market gained 2.3%) | -9.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 3.9 percentage points (the stock lost 0.9% while the market gained 3.1%) | -4.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 8.6 percentage points (the stock gained 2.5% while the market gained 11.1%) | -8.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 32.2 percentage points (the stock gained 52.7% while the market gained 20.5%) | +32.2% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thin, spanning 1.9% of the share price, which is taken to mean a barrier that gives way easily. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $15.36 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +6.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $16.23 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +0.6% |
Price levels it has turned at before
VTRS last closed at $16.32 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $15.95 | Support | 2.3% below the last close | turned there three times · 2026-05-19 to 2026-08-14 |
| $16.70 | Resistance | 2.3% above the last close | turned there twice · 2026-05-26 to 2026-06-12 |
| $13.49 | Support | 17.3% below the last close | turned there three times · 2024-11-07 to 2026-01-14 |
| $12.89 | Support | 21.0% below the last close | turned there twice · 2026-01-29 to 2026-03-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · lagging the market · At the bottom of its 14-day range (stochastic below 20) · Trading inside the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.20 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$18.50 range $12.00 – $23.00; median $19.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for VTRS
- Consensus EPS estimate$0.65 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant debt levels and compliance with financial covenants like the Maximum Leverage Ratio","Exposure to ongoing and future litigation settlements and legal contingencies","Risks associated with integrating acquisitions and executing enterprise-wide strategic reviews"]
What changed in the latest 10-Q
AI-assisted comparison of VTRS's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- In March 31, 2026 filing: Specific notation that currency impact was $161.8 million favorable, primarily from EU and China currency changes
- In March 31, 2026 filing: Breakdown of new product sales ($70.7 million) and net base business growth ($34.0 million)
- In March 31, 2026 filing: Geographic net sales breakdown with North America at $828.1 million and Europe at $1.19 billion
- In March 31, 2026 filing: Reference to $71.9 million inventory and fixed asset write-off from Nashik manufacturing facility fire
- In March 31, 2026 filing: R&D expense increased to $248.6 million with specific mention of selatogrel and cenerimod development programs
- Removed:
- September 30, 2025 filing: References to 'Indore Impact' throughout (mentioned multiple times in older filing as approximately $100 million impact)
- September 30, 2025 filing: Reference to divestitures that closed during 2024 and their impact on net sales
- September 30, 2025 filing: Specific mention of lenalidomide and everolimus product declines
- September 30, 2025 filing: R&D expense discussion section (appears truncated in newer filing)
- Reworded:
- Reporting period changed from September 30, 2025/2024 to March 31, 2026/2025
- Total revenues comparison changed from 'essentially flat' (0%) to 8% increase
- Net sales comparison changed from 'essentially flat' (0%) to 8% increase
- Total net sales dollar amounts changed from $3.75 billion range to $3.51 billion range
- Gross profit margins changed from 36%/39% to 33% (GAAP) with adjusted margins stable at 56%
- Cost of sales increased from $2.39 billion to $2.36 billion range
- Top ten products concentration increased from 38%/36% to 40%/38%
- Notes:
- The two filings report on different quarters (Q3 2025 vs Q1 2026) with different comparison periods (Q3 2024 vs Q1 2025), limiting direct comparability
- The older filing appears truncated at the end of the R&D section, preventing full comparison of operating expenses discussion
- Different business events between periods (Indore manufacturing issue in 2025; Nashik fire in 2026) affect comparability of cost structures
Risk Factors
- Added:
- Added '2025 Form 10-K' definition: 'Viatris' annual report on Form 10-K for the fiscal year ended December 31, 2025' (filed 2026-05-07)
- Added 'EWSR' definition: 'Enterprise-wide strategic review' (filed 2026-05-07)
- Removed:
- Removed 'Biocon Biologics Transaction' definition regarding biosimilars portfolio contribution (filed 2025-11-06)
- Removed 'CNS' definition: 'Central Nervous System' (filed 2025-11-06)
- Removed 'Indore Impact' definition regarding FDA warning letter and supply disruptions impact on 2025 revenues (filed 2025-11-06)
- Removed 'OTC Transaction' definition describing the October 2023 announcement and July 2024 closure (filed 2025-11-06)
- Removed 'SARs' definition: 'Stock appreciation rights' (filed 2025-11-06)
- Reworded:
- Changed Form 10-Q period reference from 'September 30, 2025' to 'March 31, 2026' (filed 2026-05-07)
- Changed 'Form 10-K' reference from '2024 Form 10-K for the fiscal year ended December 31, 2024, as amended' to '2025 Form 10-K for the fiscal year ended December 31, 2025' (filed 2026-05-07)
- Notes:
- The newer filing text appears truncated at the end of the glossary section; comparison is limited to the text provided
- Page number references changed from older filing (page 76-79 for ITEM 1A-6) to newer filing (page 59-61), but this reflects document restructuring rather than content change
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($809784) — 1 selling insider
- Last 180 days0 buys · 2 sells ($1M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-25. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about VTRS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for VTRS from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding VTRS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 159,250,056
- Reported value $2,151,468,280
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
VTRS had 45,687,489 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
VTRS had 3.98% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.8 days to cover at the same settlement.
- Reported short interest (shares) 45,687,489
- Short interest (% of shares outstanding) 3.98%
- Prior settlement (shares) 47,215,480
- Reported change -3.24%
- Days to cover (reported) 4.8
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Teva Pharmaceutical Industries (TEVA)
- Sandoz Group (SDZNY)
- Hikma Pharmaceuticals
- Amneal Pharmaceuticals (AMRX)
- Dr. Reddy's Laboratories (RDY)
- Sun Pharmaceutical Industries (SUNPHARMA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VTRS vs…
Frequently asked questions
What does Viatris (VTRS) do?
Viatris is a global pharmaceutical company focused on providing access to medicine through a diverse portfolio of branded, generic, and complex pharmaceutical products. The company operates globally across segments including Developed Markets, Emerging Markets, Greater China, and JANZ, and has recently invested in clinical development programs like selatogrel and cenerimod. Viatris was formed through the combination of Mylan and Pfizer's Upjohn Business.
What sector is Viatris (VTRS) in?
Viatris (VTRS) is classified in the Health Care sector. Its industry is generic and specialty pharmaceuticals. It trades on NASDAQ.
Does VTRS pay a dividend?
Yes — Viatris (VTRS) pays a dividend, with an indicated yield of about 2.70% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Viatris's (VTRS) competitors?
Notable peers of Viatris (VTRS) include Teva Pharmaceutical Industries, Sandoz Group, Hikma Pharmaceuticals, Amneal Pharmaceuticals and Dr. Reddy's Laboratories. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in VTRS?
Yes — we hold 4 matched STOCK Act disclosures for VTRS from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Viatris (VTRS) overbought or oversold right now?
Viatris (VTRS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 45, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VTRS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.